Global Market Study on GMP Cell Banking Services: Mammalian Cell Type Segment Revenue Projected to Grow 3.2x by 2025 End as Compared to that in 2017


Gmp Cell Banking Service Market
  • Published On : May-2017 |
  • Pages : 164 Pages |
  • Format :

Service providers in the global GMP cell banking services market are focusing on offering innovative services to retain market share. For instance, key players in the global GMP cell banking services market are focusing on the development of new and innovative service models and expanding the existing capacity. Providers are also adopting innovative marketing strategies to gain market share. Balancing fixed costs while offering competitive pricing is a major focus area for vendors in this market. For example, biopharmaceutical companies are focusing on outsourcing the manufacturing of biologics to the APAC region in order to reduce their manufacturing costs and thus set competitive pricing. Another strategy that key players are adopting in this market is increasing storage capacity and offering end-to-end services across all the nodes of the value chain. Companies are also entering into mergers and acquisitions as well as partnering with small biotech startups to expand service offerings, capacity and market presence globally.

In a new publication titled “GMP Cell Banking Services Market: Global Industry Analysis and Forecast, 2017–2025,” Persistence Market Research analysts have targeted five key geographies and have observed that North America represents the most lucrative market, followed by Europe and Asia Pacific. The GMP cell banking services market in MEA is expected to record comparatively less growth due to low awareness about these services and presence of limited manufacturing facilities.

The U.S. Food and Drug Administration guidance on contract manufacturing

The U.S. Food and Drug Administration issued its first guidance for quality agreements between pharmaceutical companies and CMOs in November 2016. The following is the regulatory overview of the FDA regarding contract manufacturing.

  • All manufacturing facilities to ensure compliance with cGMP regulations
  • Requirement of a quality unit in pharmaceutical companies to monitor adherence to regulations by a CMO
  • Various ICH guidelines have been published that are relevant to cGMP recommendations for contract manufacturing arrangements
  • Requirement of quality unit activities to be in writing

Report Description

The main focus of this report is on the process workflow of cell banking services. Various checkpoints are in place during the overall cell banking process to ensure quality and consistency of culture, as well as on avoiding contaminants. To make this report an exclusive one, the expert team of analysts have given an optimistic scenario, likely scenario and conservative scenario. The analysts have segmented the market into two main categories – cell type and end user – and have analyzed these segments across the assessed regions. The report executive summary succinctly covers the market overview, overall market approach, target geographies and differentiating strategies of the global GMP cell banking services market key players. The executive summary section is followed by the market introduction and consists of a thorough description of the various types of cells.

The report presents a detailed analysis of the GMP cell banking services market scenario. This analysis includes Y-o-Y growth and absolute $ opportunity analysis for the projected period. The market dynamics section focuses on the drivers, restraints, opportunities and trends likely to impact the global GMP cell banking services market. The analysts have made sure to cover each and every segment in detail along with highlighting the market share analysis, BPS analysis and the Y-o-Y growth rate of global GMP cell banking services. Finally, the report concludes with key player profiles accompanied by market developments, an overview of business strategies and SWOT analysis.

Market Segmentation

By Region

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • MEA

By Cell Type

  • Mammalian
  • Microbial
  • Insect
  • Yeast
  • Avian
  • Stem Cell
  • Others

By End User

  • Biopharmaceutical Companies
  • Contract Manufacturing Organizations

Research Methodology

The global GMP cell banking services market value is calculated based on the cell banks used to develop biopharmaceuticals. However, the analysts have excluded cord cell banking services that are not a part of GMP based cell banking services. Indicators such as R&D expenditure, research funding from government and non-profit organizations, etc. have been considered to arrive at the estimated market numbers. All information has been triangulated through validation of primary research data. Yearly change in inflation rate has not been factored in while forecasting market numbers. Top-down approach has been used to calculate the market sizing, while bottom-up approach by GMP cell bank types has been used to counter-validate the market estimations.

Mammalian cell type segment is the most attractive segment in the global GMP cell banking services market

Mammalian segment dominated the global GMP cell banking services market in terms of revenue in 2016 and the trend is projected to continue throughout the forecast period. The mammalian segment is the most attractive segment with attractiveness index of 5 over the forecast period. The segment is expected to expand at 15.6% CAGR over the forecast period and be valued close to US$ 690 Mn by 2025 end. The mammalian segment accounted for more than 60% revenue share of the global GMP cell banking services market in 2016 and is expected to gain 556 basis points in its market share by 2025 over 2017. Mammalian cell type segment is projected to create absolute $ opportunity of more than US$ 30 Mn in 2018 over 2017.  Revenue from the mammalian segment in the global GMP cell banking services market is expected to grow 3.2x by 2025 end as compared to that in 2017. 

Limited in-house storage and testing capabilities is a main factor boosting the global GMP cell banking services

Global biopharmaceutical companies are making a more significant commitment to outsourcing by striving to improve operating efficiency and increase pipeline productivity. Biotechnology companies and other private organizations have always preferred outsourcing to investing in internal infrastructure. Academic institutions are also partnering with biopharmaceutical companies to monetize innovation and acquire expertise in drug discovery and development.

Some of the most promising new therapies are being discovered by small biotechnology companies supported by venture capital funds, capital markets as well as large biopharmaceutical companies. These companies are expected to continue to invest in their pipelines due to the continuing availability of funding. Additionally, biopharmaceutical companies prefer to outsource manufacturing in markets where they have limited expertise in various stages of the value chain, especially towards the end where a CDMO’s presence in a particular region gives them access to a vast distribution network, as well as knowledge of existing regulatory guidelines. These factors drive the growth of the global GMP cell banking services market.

Large biopharmaceutical companies have several manufacturing sites that typically produce commercially marketed therapeutics as well as material for clinical development. As a result, the in-house capacity for storage of GMP cell banks is limited. Cell banking service providers have the required infrastructure in place, such as designated clean rooms and trained personnel, and also ensure adherence to regulatory guidelines such as ICH, thereby making them an ideal partner for biopharmaceutical companies. They are also able to provide in-house testing services or sub-contract these to certified testing laboratories. Limited in-house storage and testing capabilities are likely to fuel the growth of the global GMP cell banking services market.

gmp cell banking services market

Mammalian cell type segment is predicted to dominate the key regional GMP cell banking services markets in terms of revenue

The mammalian cell type segment dominated the North America GMP cell banking services market in revenue terms in 2016 and is projected to continue to do so throughout the forecast period. The mammalian cell type segment is the most attractive segment in the North America regional market, recording an attractiveness index of 5.1 over the forecast period. The mammalian segment is also the most attractive segment by cell type in the Latin America GMP cell banking services market with an attractiveness index of 4.5 over the period of forecast. In the Europe GMP cell banking services market, revenue from the mammalian segment is anticipated to increase at a CAGR of 13.3% over 2017-2025 to reach more than US$ 200 Mn by 2025. The mammalian segment dominated the Asia Pacific GMP cell banking services market in terms of revenue in 2016, and the trend is projected to continue throughout the forecast period.

Company Profiles

  • WuXi AppTec
  • Charles River Laboratories International, Inc.
  • Eurofins Scientific
  • Merck KGaA
  • Lonza Group Ltd
  • SGS Ltd
  • ViruSure GmbH
  • Austrianova
  • Goodwin Biotechnology Inc.
  • Paragon Bioservices, Inc.
  • Others
Back To Top